About this trial
This is a multi-centre, single blind, randomized study. Patients admitted to hospital with acute decompensated heart failure will be randomized to biomarker guided discharge algorithm vs usual care in a 2:1 ratio. NTproBNP and other biomarkers will be measured within 24 hours of admission. The NTproBNP results will be used to further stratify participants randomized to the biomarker guided group into lower and medium to higher risk pathways. Biomarkers will be repeated after 2-3 days and again prior to discharge. Specific care pathways will be followed for each of the lower risk and medium-higher risk groups. Biomarkers will be repeated 30 days post discharge. Participants will be followed with a phone call at 3 months and return for a follow up visit at 6 months post discharge for outcome evaluation.
Eligibility criteria
Qualifiers
Patients admitted to hospital with a primary diagnosis of acute decompensated heart failure, compatible with the modified Framingham criteria
Disqualifiers
Patient unable to provide blood samples or cannot participate in follow-up
Patient with end stage organ failure
Kidney: creatinine >350 μmol/L or Estimated GFR ≤15 ml/min
Liver dysfunction: liver function test >2.5 times normal
Trial design
Treatments tested in this trial
- Biomarker guided discharge algorithm
Treatment groups
Sponsors and collaborators
Ottawa Heart Institute Research Corporation
Lead sponsor
Genome Canada
Collaborator
Roche Diagnostics GmbH
Collaborator